AstraZeneca has said that it will stop a Phase III trial of its chronic lymphocytic leukaemia drug Calquence (acalabrutinib) early after the drug met its primary endpoint in an interim anal
BenevolentAI is embarking on another round of job losses, closing its US office, and shelving its software-as-a-service business to extend its cash reserves into the third
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.